

Mean # of lung metastases




Figure 1

Heparin Binding Domain Peptide

Liposomal Lipid A




Figure 2

Title: Compositions and Methods for Treating Cancer
Hyperproliferative Disorders
Inventors: John Holaday; Antonio Ruiz; John Madsen; Stacy Plum



HEPARIN BINDING DOMAIN



LLA CONTROL

Figure 3




Figure 4

Title: Compositions and Methods for Treating Cancer
Hyperproliferative Disorders
Inventors: John Holaday; Antonio Ruiz; John Madsen; Stacy Plum




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9

Title: Compositions and Methods for Treating Cancer
Hyperproliferative Disorders
Inventors: John Holaday; Antonio Ruiz; John Madsen; Stacy Plum




Figure 10

Title: Compositions and Methods for Treating Cancer
Hyperproliferative Disorders
Inventors: John Holaday; Antonio Ruiz; John Madsen; Stacy Plum




Figure 11





Figure 12




Figure 13




Figure 14

Title: Compositions and Methods for Treating Cancer
Hyperproliferative Disorders
Inventor: John Holaday; Antonio Ruiz; John Madsen; Stacy Plum




Figure 15






Figure 16





Figure 17

Title: Compositions and Methods for Treating Cancer
Hyperproliferative Disorders
Inventor: John Holaday; Antonio Ruiz; John Madsen; Stacy Plum

BEST AVAILABLE COPY




Figure 18

Figure 19: Overview





Figure 20: ENMD-0996 induces long-term protection against tumor challenge in mice

Challenge date	Treatment	Activity in B16BL6 Mean number of metastasis T/C
2 Weeks	ENMD-0996	47 ± 37 0.20
2 Weeks	Control	234 ± 82 1.00
3 Months	ENMD-0996	61 ± 42 0.24
3 Months	Control	252 ± 62 1.00

Figure 21: Sera from ENMD-0996-treated Mice
Inhibit the Binding of Heparin Sulfate to FGF-2



Reciprocal Dilution of Antisera


Figure 22. The antibody response in mice treated with ENMD-0996 is specific for FGF-2

Antigen	Antibody Titer
Basic FGF/FGF-2	1:5000
Acidic FGF/FGF-1	< 1:100
FGF-3	< 1:100
FGF-4	< 1:100
FGF-5	< 1:100
FGF-6	< 1:100
FGF-7	< 1:100
FGF-9	< 1:100
FGF-10	< 1:100
FGF-17	< 1:100
VEGF	< 1:100
TFPI	< 1:100


Figure 23: ENMD-0996 does not inhibit metastasis in mice lacking functional B- and T-cells

Treatment	Mice	Mean number of Metastasis (\pm SD)	T/C
PBS Control Liposomes ENMD-0996	C57BL/6	105 \pm 16	1.00
	C57BL/6	146 \pm 29	1.40
	C57BL/6	37 \pm 5	0.35
PBS Control Liposomes ENMD-0996	C57BL/6 SCID/SCID	103 \pm 18	1.00
	C57BL/6 SCID/SCID	100 \pm 22	0.97
	C57BL/6 SCID/SCID	86 \pm 28	0.83

Figure 24: Mice Treated with ENMD-0996
Develop a Delayed Type Hypersensitivity to
Subsequent Challenge with FGF-2



**Figure 25. Treatment of Mice with ENMD-0996
Results in the Production of IFN γ Production**



**Figure 26: Splenocytes from mice treated with ENMD-0996
produce IFN γ in response to FGF-2 or HBD**

